Meet an IMDA Member - OE Meyer Co
president sales and marketing
OE Meyer is an anesthesia/respiratory specialty dealer
focused on helping our customers navigate the complex healthcare
landscape and address product fulfillment needs and services.
Doing what's right has resulted in long-standing customer
relationships and satisfaction.
In today's environment of healthcare supplier consolidation, it
can be frustrating when suppliers seem more focused on internal
interests than on you. OE Meyer Co. is a diverse team of problem
solvers that deliver continuity of service, expertise, and
consistent representation. We'll be there when you need
convenient, cost-effective, and comprehensive solutions.
Here's what you can expect from OE Meyer Co.:
Professionally trained employee owners.
Same day shipping for orders placed by 3:00 p.m. EST.
99 percent of established product orders ship same day.
Customer-based shipping preferences. Dedicated OE Meyer Co.
drivers can deliver to many customer locations, or within
1-2 days via common carrier.
Product samples: Just ask. We can help.
No-hassle return policy.
says the big guys can't play in the innovation game? Given
how much money big medical device companies spend each year on
acquisitions, it's clear that they have a desire for innovation.
And yet, they hold back on R&D spending because large
corporations tend to need predictability, repeatability and
scalability. But that doesn't have to be the case, said
Steve Geist, a director of R&D at Edwards Lifesciences,
speaking at MD&M Minneapolis recently. Here are five reasons
why: Big guys have 1) an R&D infrastructure in place; they just
have to fix it so it becomes less of an exercise in
documentation and more of a basis for actual engineering; 2)
tools and capabilities that small companies don't; 3) the talent
to innovate, though they have to unleash it; 4) the right
contacts among clinicians and key opinion leaders; and 5) deeper
pockets than small companies.
Health technology hazards identified. Ransomware and other
cybersecurity threats were deemed the No. 1 health technology
hazard by ECRI Institute, as it launched its
Top 10 Health Technology Hazards list for 2018. Multiple
ransomware and other malware variants have infected healthcare
organizations, as well as other private and public
organizations, throughout the world, according to the company.
Endoscope reprocessing remains in the No. 2 spot this year, as
healthcare facilities continue to struggle with consistently and
effectively cleaning, disinfecting, and sterilizing instruments
systems: Customers or suppliers? Where are the
next-generation medical technologies coming from? Could be from
one of your customer's "Innovation Centers." Last week, Partners
HealthCare System in Boston announced the closing of $171.1
million in capital to invest in early-stage life sciences
companies. That same week, Texas Medical Center launched a $25
million venture fund to support early-stage companies developing
healthcare technologies. And in September, the Cedars-Sinai
accelerator kicked off its third class of healthcare startups.
Companies receive an investment of $120,000; mentorship from
Cedars-Sinai physicians, researchers, healthcare professionals
and executives; and dedicated office space in the Cedars-Sinai
Innovation Space, adjacent to the medical center in Los Angeles.
CDI @ TMC. Johnson &
Johnson Medical Devices Companies opened the Center for Device
Innovation at the Texas Medical Center (CDI @ TMC), a
collaboration with Johnson & Johnson Innovation LLC and Texas
Medical Center to accelerate development -from concept to
commercialization-of medical devices technologies. J&J says the
26,000-square-foot facility is appointed with all the tools its
staff may need to translate ideas to products, including a
machine shop, a mechanical testing lab, an electronics workspace
and component lab, a 3D printing lab and a virtual reality
Parenteral solutions shortage must be addressed. The
American Hospital Association urged the Food and Drug
Administration to take action to address the shortages of
small-volume parenteral solutions, such as 50 and 100 milliliter
injection bags of sodium chloride 0.9 percent, dextrose 5
percent, and IV nutritional products. "The AHA understands and
appreciates that FDA has been working with Baxter and other
major manufacturers of these products to address the current
shortages," said AHA Executive Vice President Thomas Nickels, in
Nov. 7 letter to FDA Commissioner Scott Gottlieb, M.D. "We
also appreciate your efforts to obtain alternative sources of
the products, including from overseas suppliers. However, we
strongly urge FDA to do more by pushing current manufacturers to
not only continue to produce these products at their maximum
capacity, but also to make investments to ensure an increasing
supply for the future."